GLP-1 therapy is appropriate for many older patients but requires more careful monitoring around sarcopenia, polypharmacy, falls risk, and Medicare coverage specifics.
Medicare coverage
Medicare Part D still excludes drugs used only for weight loss. From July 1, 2026 through December 31, 2027, the CMS Medicare GLP-1 Bridge gives eligible Medicare Part D enrollees a $50 copay for Foundayo, Wegovy or the Zepbound KwikPen. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; Medicare.gov says their Part D plan might cover a GLP-1 for those conditions. See our Medicare Part D page.
Sarcopenia is the central concern
Adults over 65 lose ~1–2% muscle/year without intervention. Rapid weight loss without resistance training compresses years of normal sarcopenia into months. Resistance training is not optional.
Falls risk
Sarcopenia + weight loss + GI symptoms (dehydration, weakness) can elevate falls risk. Adequate hydration; conservative titration; coordination with primary care.
Polypharmacy
Older patients typically on multiple medications. GLP-1 interactions — particularly insulin/sulfonylureas (hypoglycemia), levothyroxine (absorption), NSAIDs (renal risk). See drug interactions.
Cognitive screening
If you have cognitive concerns, coordinate with primary care. Adherence to dosing schedule and recognition of concerning symptoms requires intact cognition.
Bone density
Especially in women postmenopause. Resistance training + calcium + vitamin D + DEXA monitoring per physician.